Activity of Artemisia annua and artemisinin derivatives, in prostate carcinoma
- Publication type:
- Journal article
- Metadata:
-
- Autoren
- Friedrich-Wilhelm Michaelsen
- Mohamed EM Saeed
- Joerg Schwarzkopf
- Thomas Efferth
- Autoren-URL
- https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000366983400003&DestLinkType=FullRecord&DestApp=WOS_CPL
- DOI
- 10.1016/j.phymed.2015.11.001
- Externe Identifier
- Clarivate Analytics Document Solution ID: CZ3DA
- PubMed Identifier: 26655404
- ISSN
- 0944-7113
- Ausgabe der Veröffentlichung
- 14
- Zeitschrift
- PHYTOMEDICINE
- Schlüsselwörter
- Asteraceae
- Drug resistance
- PSA, Sesquiterpene
- Tumor imaging
- Tumor marker
- Paginierung
- 1223 - 1231
- Datum der Veröffentlichung
- 2015
- Status
- Published
- Titel
- Activity of <i>Artemisia annua</i> and artemisinin derivatives, in prostate carcinoma
- Sub types
- Article
- Ausgabe der Zeitschrift
- 22
Data source: Web of Science (Lite)
- Other metadata sources:
-
- Autoren
- Friedrich-Wilhelm Michaelsen
- Mohamed EM Saeed
- Jörg Schwarzkopf
- Thomas Efferth
- DOI
- 10.1016/j.phymed.2015.11.001
- ISSN
- 0944-7113
- Ausgabe der Veröffentlichung
- 14
- Zeitschrift
- Phytomedicine
- Sprache
- en
- Paginierung
- 1223 - 1231
- Datum der Veröffentlichung
- 2015
- Status
- Published
- Herausgeber
- Elsevier BV
- Herausgeber URL
- http://dx.doi.org/10.1016/j.phymed.2015.11.001
- Datum der Datenerfassung
- 2019
- Titel
- Activity of Artemisia annua and artemisinin derivatives, in prostate carcinoma
- Ausgabe der Zeitschrift
- 22
Data source: Crossref
- Abstract
- <h4>Background</h4>Artemisia annua L, artemisinin and artesunate reveal profound activity not only against malaria, but also against cancer in vivo and clinical trials. Longitudinal observations on the efficacy of A. annua in patients are, however missing as of yet.<h4>Methods</h4>Clinical diagnosis was performed by imaging techniques (MRT, scintigraphy, SPECT/CT) and blood examinations of standard parameters from clinical chemistry. Immunohistochemistry of formalin-fixed, paraffin-embedded tumor material was performed to determine the expression of several biomarkers (cycloxygenase-2 (COX2), epidermal growth factor receptor (EGFR), glutathione S-transferase P1 (GSTP1), Ki-67, MYC, oxidized low density lipoprotein (lectin-like) receptor 1 (LOX1), p53, P-glycoprotein, transferrin receptor (TFR, CD71), vascular endothelial growth factor (VEGF), von Willebrand factor (CD31)). The immunohistochemical expression has been compared with the microarray-based mRNA expression of these markers in two prostate carcinoma cell lines (PC-3, DU-145).<h4>Results</h4>A patient with prostate carcinoma (pT3bN1M1, Gleason score 8 (4+4)) presented with a prostate specific antigen (PSA) level >800 µg/l. After short-term treatment with bacalitumide (50 mg/d for 14 days) and long-term oral treatment with A. annua capsules (continuously 5 × 50 mg/d), the PSA level dropped down to 0.98 µg/l. MRT, scintigraphy and SPECT/CT verified tumor remission. Seven months later, PSA and ostase levels increased, indicating tumor recurrence and skeletal metastases. Substituting A. annua capsules by artesunate injections (2 × 150 mg twice weekly i.v.) did not prohibit tumor recurrence. PSA and ostase levels rose to 1245 µg/l and 434 U/l, respectively, and MRT revealed progressive skeletal metastases, indicating that the tumor acquired resistance. The high expression of MYC, TFR, and VEGFC in the patient biopsy corresponded with high expression of these markers in the artemisinin-sensitive PC-3 cells compared to artemisinin-resistant DU-145 cells.<h4>Conclusion</h4>Long-term treatment with A. annua capsules combined with short-term bicalitumide treatment resulted in considerable regression of advanced metastasized prostate carcinoma. Controlled clinical trials are required to evaluate the clinical benefit of A. annua in prostate cancer.
- Addresses
- Practice for Naturopathy, 29499 Zernien, Germany.
- Autoren
- Friedrich-Wilhelm Michaelsen
- Mohamed EM Saeed
- Jörg Schwarzkopf
- Thomas Efferth
- Thomas Efferth
- DOI
- 10.1016/j.phymed.2015.11.001
- eISSN
- 1618-095X
- Externe Identifier
- PubMed Identifier: 26655404
- Open access
- false
- ISSN
- 0944-7113
- Ausgabe der Veröffentlichung
- 14
- Zeitschrift
- Phytomedicine : international journal of phytotherapy and phytopharmacology
- Schlüsselwörter
- Cell Line, Tumor
- Humans
- Artemisia annua
- Bone Neoplasms
- Prostatic Neoplasms
- Neoplasm Metastasis
- Artemisinins
- Prostate-Specific Antigen
- Immunohistochemistry
- Drug Resistance, Neoplasm
- Aged, 80 and over
- Male
- Biomarkers, Tumor
- Artesunate
- Sprache
- eng
- Medium
- Print-Electronic
- Online publication date
- 2015
- Paginierung
- 1223 - 1231
- Datum der Veröffentlichung
- 2015
- Status
- Published
- Datum der Datenerfassung
- 2015
- Titel
- Activity of Artemisia annua and artemisinin derivatives, in prostate carcinoma.
- Sub types
- Journal Article
- Ausgabe der Zeitschrift
- 22
Data source: Europe PubMed Central
- Abstract
- BACKGROUND: Artemisia annua L, artemisinin and artesunate reveal profound activity not only against malaria, but also against cancer in vivo and clinical trials. Longitudinal observations on the efficacy of A. annua in patients are, however missing as of yet. METHODS: Clinical diagnosis was performed by imaging techniques (MRT, scintigraphy, SPECT/CT) and blood examinations of standard parameters from clinical chemistry. Immunohistochemistry of formalin-fixed, paraffin-embedded tumor material was performed to determine the expression of several biomarkers (cycloxygenase-2 (COX2), epidermal growth factor receptor (EGFR), glutathione S-transferase P1 (GSTP1), Ki-67, MYC, oxidized low density lipoprotein (lectin-like) receptor 1 (LOX1), p53, P-glycoprotein, transferrin receptor (TFR, CD71), vascular endothelial growth factor (VEGF), von Willebrand factor (CD31)). The immunohistochemical expression has been compared with the microarray-based mRNA expression of these markers in two prostate carcinoma cell lines (PC-3, DU-145). RESULTS: A patient with prostate carcinoma (pT3bN1M1, Gleason score 8 (4+4)) presented with a prostate specific antigen (PSA) level >800 µg/l. After short-term treatment with bacalitumide (50 mg/d for 14 days) and long-term oral treatment with A. annua capsules (continuously 5 × 50 mg/d), the PSA level dropped down to 0.98 µg/l. MRT, scintigraphy and SPECT/CT verified tumor remission. Seven months later, PSA and ostase levels increased, indicating tumor recurrence and skeletal metastases. Substituting A. annua capsules by artesunate injections (2 × 150 mg twice weekly i.v.) did not prohibit tumor recurrence. PSA and ostase levels rose to 1245 µg/l and 434 U/l, respectively, and MRT revealed progressive skeletal metastases, indicating that the tumor acquired resistance. The high expression of MYC, TFR, and VEGFC in the patient biopsy corresponded with high expression of these markers in the artemisinin-sensitive PC-3 cells compared to artemisinin-resistant DU-145 cells. CONCLUSION: Long-term treatment with A. annua capsules combined with short-term bicalitumide treatment resulted in considerable regression of advanced metastasized prostate carcinoma. Controlled clinical trials are required to evaluate the clinical benefit of A. annua in prostate cancer.
- Date of acceptance
- 2015
- Autoren
- Friedrich-Wilhelm Michaelsen
- Mohamed EM Saeed
- Jörg Schwarzkopf
- Thomas Efferth
- Autoren-URL
- https://www.ncbi.nlm.nih.gov/pubmed/26655404
- DOI
- 10.1016/j.phymed.2015.11.001
- eISSN
- 1618-095X
- Ausgabe der Veröffentlichung
- 14
- Zeitschrift
- Phytomedicine
- Schlüsselwörter
- Asteraceae
- Drug resistance
- PSA, Sesquiterpene
- Tumor imaging
- Tumor marker
- Aged, 80 and over
- Artemisia annua
- Artemisinins
- Artesunate
- Biomarkers, Tumor
- Bone Neoplasms
- Cell Line, Tumor
- Drug Resistance, Neoplasm
- Humans
- Immunohistochemistry
- Male
- Neoplasm Metastasis
- Prostate-Specific Antigen
- Prostatic Neoplasms
- Sprache
- eng
- Country
- Germany
- Paginierung
- 1223 - 1231
- PII
- S0944-7113(15)00332-3
- Datum der Veröffentlichung
- 2015
- Status
- Published
- Datum, an dem der Datensatz öffentlich gemacht wurde
- 2016
- Titel
- Activity of Artemisia annua and artemisinin derivatives, in prostate carcinoma.
- Sub types
- Journal Article
- Ausgabe der Zeitschrift
- 22
Data source: PubMed
- Beziehungen:
- Property of